AmCad BioMed
AmCad BioMed Corporation (AmCad), founded in 2008 and listed on Taipei Exchange in 2015, develops innovative AI-powered ultrasound Computer-Assisted Detection (CAD) devices for early and accurate medical diagnosis. Their FDA-cleared and CE-certified products include AmCAD-UT® for thyroid cancer analysis, AmCAD-UO for obstructive sleep apnea detection, AmCAD-US for backscattered signal analysis, AmCAD-UV for pulsatile signal classification, and AmCAD-CA for cytopathology analysis. AmCad integrates AI with hardware solutions to provide detailed sonographic visualization and quantification, addressing unmet medical needs in thyroid cancer, fatty liver, liver fibrosis, and sleep apnea. The company pioneers ultrasound AI technology to enhance clinical decision-making and improve healthcare efficiency globally.
AmCad BioMed
AmCad BioMed Corporation (AmCad), founded in 2008 and listed on Taipei Exchange in 2015, develops innovative AI-powered ultrasound Computer-Assisted Detection (CAD) devices for early and accurate medical diagnosis. Their FDA-cleared and CE-certified products include AmCAD-UT® for thyroid cancer analysis, AmCAD-UO for obstructive sleep apnea detection, AmCAD-US for backscattered signal analysis, AmCAD-UV for pulsatile signal classification, and AmCAD-CA for cytopathology analysis. AmCad integrates AI with hardware solutions to provide detailed sonographic visualization and quantification, addressing unmet medical needs in thyroid cancer, fatty liver, liver fibrosis, and sleep apnea. The company pioneers ultrasound AI technology to enhance clinical decision-making and improve healthcare efficiency globally.